ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney

Physiological Reports

Volumn 2, Issue 3, 2014, Pages

  Wysocki, Jan ^a   Ortiz Melo, David I ^b   Mattocks, Natalie K ^b   Xu, Katherine ^b   Prescott, Jessica ^b   Evora, Karla ^a   Ye, Minghao ^a   Sparks, Matthew A ^b   Haque, Syed K ^a   Batlle, Daniel ^a   Gurley, Susan B ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

ACE2; Kidney disease; Reactive oxygen species; Renin angiotensin system

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 8 ISOPROSTANE; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7]; CATALASE; HYDROGEN PEROXIDE; LOSARTAN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; KIDNEY CORTEX; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEGRADATION; TELEMETRY; URINALYSIS;

EID: 85009108008     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.1002/phy2.264     Document Type: Article

References (48)

1. Agarwal, R., R. C. Campbell, D. G. Warnock. 2004. Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. Semin. Nephrol. 24: 101-114.
2. Allred, A. J., D. I. Diz, C. M. Ferrario, M. C. Chappell. 2000. Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. Am. J. Physiol. Renal Physiol. 279: F841-F850.
3. Alvarez, Y., A. M. Briones, R. Hernanz, J. V. Perez-Giron, M. J. Alonso, M. Salaices. 2008. Role of NADPH oxidase and iNOS in vasoconstrictor responses of vessels from hypertensive and normotensive rats. Br. J. Pharmacol. 153: 926-935.
4. Billet, S., F. Aguilar, C. Baudry, E. Clauser. 2008. Role of angiotensin II AT1 receptor activation in cardiovascular diseases. Kidney Int. 74: 1379-1384.
5. Block, K., Y. Gorin, P. Hoover, P. Williams, T. Chelmicki, R. A. Clark, et al. 2007. NAD(P)H oxidases regulate HIF-2alpha protein expression. J. Biol. Chem. 282: 8019-8026.
6. Brenner, B. M., M. E. Cooper, D. de Zeeuw, W. F. Keane, W. E. Mitch, H. H. Parving, et al. 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345: 861-869.
7. Butz, G. M., R. L. Davisson. 2001. Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. Physiol. Genomics 5: 89-97.
8. Chappell, M. C., A. J. Allred, C. M. Ferrario. 2001. Pathways of angiotensin-(1-7) metabolism in the kidney. Nephrol. Dial. Transplant. 16(Suppl 1): 22-26.
9. Crackower, M., R. Sarao, G. Oudit, C. Yagil, I. Kozieradzki, S. Scanga, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828.
10. Crowley, S. D., C. W. Frey, S. K. Gould, R. Griffiths, P. Ruiz, J. L. Burchette, et al. 2008. Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am. J. Physiol. Renal Physiol. 295: F515-F524.
11. Dahlof, B., R. B. Devereux, S. E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003.
12. Dong, B., C. Zhang, J. B. Feng, Y. X. Zhao, S. Y. Li, Y. P. Yang, et al. 2008. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28: 1270-1276.
13. Donoghue, M., F. Hsieh, E. Baronas, K. Godbout, M. Gosselin, N. Stagliano, et al. 2000. A novel ACE-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin1-9. Circ. Res. 87: 1-9.
14. Garrido, A. M., K. K. Griendling. 2009. NADPH oxidases and angiotensin II receptor signaling. Mol. Cell. Endocrinol. 302: 148-158.
15. Gorin, Y., J. M. Ricono, B. Wagner, N. H. Kim, B. Bhandari, G. G. Choudhury, et al. 2004. Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem. J. 381: 231-239.
16. Gurley, S. B., A. Allred, T. H. Le, R. Griffiths, L. Mao, N. Philip, et al. 2006. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J. Clin. Investig. 116: 2218-2225.
17. Harrison, D. G., M. C. Gongora. 2009. Oxidative stress and hypertension. Med. Clin. North Am. 93: 621-635.
18. Huentelman, M. J., J. L. Grobe, J. Vazquez, J. M. Stewart, A. P. Mecca, M. J. Katovich, et al. 2005. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp. Physiol. 90: 783-790.
19. Ito, M., M. Oliverio, P. Mannon, C. Best, N. Maeda, O. Smithies, et al. 1995. Regulation of blood pressure by the type IA receptor for angiotensin II. Proc. Natl Acad. Sci. USA 92: 3521-3525.
20. Koitka, A., C. Tikellis. 2008. Advances in the renin-angiotensin-aldosterone system: relevance to diabetic nephropathy. ScientificWorldJournal 8: 434-445.
21. Lewis, E. J., L. G. Hunsicker, R. P. Bain, R. D. Rohde. 1993. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329: 1456-1462.
22. Massey, K. J., N. J. Hong, J. L. Garvin. 2012. Angiotensin II stimulates superoxide production in the thick ascending limb by activating NOX4. Am. J. Physiol. Cell Physiol. 303: C781-C789.
23. Miura, H., J. J. Bosnjak, G. Ning, T. Saito, M. Miura, D. D. Gutterman. 2003. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ. Res. 92: e31-e40.
24. Montezano, A. C., R. M. Touyz. 2012. Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies. Ann. Med. 44(Suppl 1): S2-S16.
25. Montuschi, P., P. J. Barnes, L. J. 2nd Roberts. 2004. Isoprostanes: markers and mediators of oxidative stress. FASEB J. 18: 1791-1800.
26. Nakane, H., F. J. Jr Miller, F. M. Faraci, K. Toyoda, D. D. Heistad. 2000. Gene transfer of endothelial nitric oxide synthase reduces angiotensin II-induced endothelial dysfunction. Hypertension 35: 595-601.
27. Nakazono, K., N. Watanabe, K. Matsuno, J. Sasaki, T. Sato, M. Inoue. 1991. Does superoxide underlie the pathogenesis of hypertension?. Proc. Natl Acad. Sci. USA 88: 10045-10048.
28. Oudit, G. Y., A. M. Herzenberg, Z. Kassiri, D. Wong, H. Reich, R. Khokha, et al. 2006. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am. J. Pathol. 168: 1808-1820.
29. Rajagopalan, S., S. Kurz, T. Munzel, M. Tarpey, B. A. Freeman, K. K. Griendling, et al. 1996. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Investig. 97: 1916-1923.
30. Sachse, A., G. Wolf. 2007. Angiotensin II-induced reactive oxygen species and the kidney. J. Am. Soc. Nephrol. 18: 2439-2446.
31. Schmid, U., H. Stopper, F. Schweda, N. Queisser, N. Schupp. 2008. Angiotensin II induces DNA damage in the kidney. Cancer Res. 68: 9239-9246.
32. Schnackenberg, C. G., W. J.Welch, C. S. Wilcox. 1998. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 32: 59-64.
33. Soler, M. J., J. Wysocki, M. Ye, J. Lloveras, Y. Kanwar, D. Batlle. 2007. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin- induced diabetic mice. Kidney Int. 72: 614-623.
34. Soler, M. J., J. Wysocki, D. Batlle. 2013. ACE2 alterations in kidney disease. Nephrol. Dial. Transplant. 28: 2687-2697.
35. Song, B., H. Jin, X. Yu, Z. Zhang, H. Yu, J. Ye, et al. 2013. Angiotensin-converting enzyme 2 attenuates oxidative stress and VSMC proliferation via the JAK2/STAT3/SOCS3 and profilin-1/MAPK signaling pathways. Regul. Pept. 185C: 44-51.
36. Stegbauer, J., T. M. Coffman. 2011. New insights into angiotensin receptor actions: from blood pressure to aging. Curr. Opin. Nephrol. Hypertens. 20: 84-88.
37. Thomas, M. C., R. J. Pickering, D. Tsorotes, A. Koitka, K. Sheehy, S. Bernardi, et al. 2010. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ. Res. 107: 888-897.
38. Tipnis, S. R., N. M. Hooper, R. Hyde, E. Karran, G. Christie, A. J. Turner. 2000. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275: 33238-33243.
39. Vickers, C., P. Hales, V. Kaushik, L. Dick, J. Gavin, J. Tang, et al. 2002. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277: 14838-14843.
40. Wagner, J., F. Gehlen, A. Ciechanowicz, E. Ritz. 1999. Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus. J. Am. Soc. Nephrol. 10: 545-551.
41. Wysocki, J., M. Ye, E. Rodriguez, F. R. Gonzalez-Pacheco, C. Barrios, K. Evora, et al. 2010. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 55: 90-98.
42. Wysocki, J., L. Garcia-Halpin, M. Ye, C. Maier, K. Sowers, K. D. Burns, et al. 2013. Regulation of urinary ACE2 in diabetic mice. Am. J. Physiol. Renal Physiol. 305: F600-F611.
43. Yagil, Y., C. Yagil. 2003. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension 41: 871-873.
44. Yamamoto, K., M. Ohishi, T. Katsuya, N. Ito, M. Ikushima, M. Kaibe, et al. 2006. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47: 718-726.
45. Ye, M., J. Wysocki, J. William, M. J. Soler, I. Cokic, D. Batlle. 2006. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J. Am. Soc. Nephrol. 17: 3067-3075.
46. Ye, M., J. Wysocki, F. R. Gonzalez-Pacheco, M. Salem, K. Evora, L. Garcia-Halpin, et al. 2012. Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. Hypertension 60: 730-740.
47. Yusuf, S., P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342: 145-153.
48. Zhong, J., D. Guo, C. B. Chen, W. Wang, M. Schuster, H. Loibner, et al. 2011. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 57: 314-322.